India’s Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats

TOKYO/MUMBAI (Reuters) – India’s Sun Pharmaceutical Industries Ltd has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, betting it can fix factory quality glitches that plagued the current owner, Japan’s Daiichi Sankyo Co , and got Ranbaxy India-made drugs barred from the United States.



Link to article: feeds.reuters.com/~r/reuters/businessNews/~3/mYR3C3DBARU/story01.htm

Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *